South Africa semaglutide compounding ruling holds while new pharmacy rules wait until 2027

South Africa semaglutide compounding has a court ruling against it but no clear rulebook yet. In June the Gauteng High Court barred iDexis, a compounding pharmacy in Tshwane, from producing medicines containing semaglutide, the ingredient in Ozempic. Daily Maverick reported on October 23 that regulators now fear the win could fade, because revised guidelines for compounding pharmacies are not expected until February or March 2027. Meanwhile complaints about fake and unregistered weight loss injections keep arriving.

What the court ordered against iDexis

The order came in a case brought by Novo Nordisk, which makes Ozempic and Wegovy. The court granted an interim interdict that stops iDexis from producing and marketing weight loss medicines containing semaglutide while regulatory investigations and further legal steps continue, EWN reported. It followed inspections by Sahpra, the national medicines regulator, and the seizure of large amounts of compounded weight loss injections at the pharmacy. In June, Sahpra also recalled products sold as iDEXIS Semaglutide, iDEXIS Tirzepatide and a combined version. A joint statement from Sahpra, the South African Pharmacy Council and the Health Professions Council said the recalled products pose a severe risk to users.

That joint statement also warned that health workers who dispensed, prescribed or kept stock of the recalled products would face disciplinary action. iDexis disputes the findings. In July it said it had told its lawyers to seek leave to appeal, and managing director Ruaan Louw said the regulator had known about its compounding since a first audit in November 2023. He said its facilities had received A grade inspection results from the Pharmacy Council. iDexis also argued that the interim order is not in the public interest. The outcome of the appeal request was not reported in the coverage we reviewed, so the order is described here as still in force on the available record.

Why regulators say compounding became manufacturing

South Africa semaglutide compounding sits under a general rule: compounding is legal only in narrow cases, such as when a patient needs a form of a medicine that no registered product offers, and it requires a prescription. Bulk preparation is allowed only when a pharmacy can show that patients regularly need the medicine. Without that evidence, "you're not compounding, you are manufacturing," Sahpra chief executive Boitumelo Semete-Makokotlela told Daily Maverick, and manufacturing needs a good manufacturing practice licence. The regulator also stresses the raw ingredient. Active ingredients must be registered in South Africa and brought in by a licensed importer, and a pharmacy licence does not cover importing them. Semete-Makokotlela said some have arrived in travellers' luggage.

Without that evidence, "you're not compounding, you are manufacturing," Sahpra chief executive Boitumelo Semete-Makokotlela told Daily Maverick, and manufacturing needs a good manufacturing practice licence.

Industry and regulators agree the court win is fragile. Stavros Nicolaou, who chairs the Pharmaceutical Task Group, called the ruling an important victory but warned that court successes can unravel when the country does not act quickly, adding, "The regulations are taking too long." Vincent Tlala, chief executive of the Pharmacy Council, said revised compounding guidelines led by Sahpra, with the council's input, are under way but not expected before February or March 2027. Until then, pharmacies work under the current rules, and enforcement depends on inspections, recalls and court cases brought one at a time. That is slow work against products that can be mixed, packed and sold online within days.

Fake weight loss drugs and retatrutide on open sale

The market outside pharmacies is the larger worry. Sahpra has received about 600 complaints since the start of this financial year about illegitimate and fake medicines sold through informal channels, online platforms and gyms, Daily Maverick reported. "We are worried that the scourge is getting out of control," said Daphne Fafudi, the regulator's head of regulatory compliance. Nicolaou said retatrutide, an experimental weight loss injection that is still in trials and has not been licensed by any regulator, is being sold openly in the country. Fake weight loss drugs of this kind carry no checked dose, no sterility testing and no clear origin, which is the core of the safety concern.

Coordination is part of the problem. On 14 October regulators, police, border officials, the revenue service and industry met in Sandton to discuss the trade. Gene Ravele of the South African Revenue Service said poor coordination between enforcement agencies is "the number one problem that organised crime is taking advantage of." A border official said detectives and prosecutors are often generalists who do not know this field. The pattern is familiar from other markets: a regulator can win one case, but supply shifts to new sellers and new routes. Our report on how Australia ended GLP 1 compounding shows a country that chose a single national rule instead.

What patients and pharmacies should do now

For patients, the regulators' advice is to get weight loss medicines only through authorised channels, such as a registered pharmacy with a prescription, and to check that the product is registered. Warning signs listed in the reporting include unusual or blank packaging, no printed expiry date, no patient leaflet, and a box that is broken or dented. "If you cannot trust the source, do not trust the medicine," Fafudi said. A seller's claim that a product is the same as a branded drug is not proof of approval. Anyone who used a recalled iDEXIS product should speak to a doctor or pharmacist rather than stop or change treatment on their own.

For pharmacies, the message from the South Africa semaglutide compounding case is that bulk mixing of semaglutide or tirzepatide without proven patient need is treated as manufacturing, with recalls and discipline as the result. Pharmacists who dispense recalled products risk action by the council. The guidelines due in 2027 should set clearer limits, and pharmacies would be wise to follow the stricter reading until then. The case also matters beyond South Africa, as cheaper generic semaglutide reaches some markets, a shift our story on new semaglutide brands in India follows. Where legitimate and affordable supply grows, regulators hope that demand for compounded and fake products will shrink over time.

Conclusion

South Africa semaglutide compounding now has a clear court signal against bulk production at iDexis, a recall of its products, and regulators warning of discipline for anyone who dispenses them. What it lacks is updated guidance for every pharmacy, which is not expected before February or March 2027. Until then, enforcement runs case by case while about 600 complaints about fake medicines show the size of the informal trade. This story is regulatory news, not medical advice.